The DOI matches its Crossref record; 287 of the 287 references it cites were found in a registry or an index.
Challenges of Antibacterial Discovery
Open accessAbstract
SUMMARY: The discovery of novel small-molecule antibacterial drugs has been stalled for many years. The purpose of this review is to underscore and illustrate those scientific problems unique to the discovery and optimization of novel antibacterial agents that have adversely affected the output of the effort. The major challenges fall into two areas: (i) proper target selection, particularly the necessity of pursuing molecular targets that are not prone to rapid resistance development, and (ii) improvement of chemical libraries to overcome limitations of diversity, especially that which is necessary to overcome barriers to bacterial entry and proclivity to be effluxed, especially in Gram-negative organisms. Failure to address these problems has led to a great deal of misdirected effort.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Molecular Basis of Bacterial Outer Membrane Permeability Revisited
Nikaido, H. (2003) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.67.4.593-656.2003 · Cited by 4,316
Baell, J. B., & Holloway, G. A. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901137j · Cited by 3,944
Mutations of bacteria from virus sensitivity to virus resistance
Luria, S. E., & Delbrück, M. (1943) · Genetics · doi:10.1093/genetics/28.6.491 · Cited by 3,894
Drugs for bad bugs: confronting the challenges of antibacterial discovery
Payne, D. J., Gwynn, M. N., Holmes, D. J., & Pompliano, D. L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2201 · Cited by 2,512
Relating protein pharmacology by ligand chemistry
Keiser, M. J., Roth, B. L., Armbruster, B. N., Ernsberger, P., Irwin, J. J., & Shoichet, B. K. (2007) · Nature Biotechnology · doi:10.1038/nbt1284 · Cited by 2,402
Antibiotics for Emerging Pathogens
Fischbach, M. A., & Walsh, C. T. (2009) · Science · doi:10.1126/science.1176667 · Cited by 1,777
Inactivation of Antibiotics and the Dissemination of Resistance Genes
Davies, J. (1994) · Science · doi:10.1126/science.8153624 · Cited by 1,730
Sampling the Antibiotic Resistome
D'Costa, V. M., McGrann, K. M., Hughes, D. W., & Wright, G. D. (2006) · Science · doi:10.1126/science.1120800 · Cited by 1,594
The antibiotic resistome: the nexus of chemical and genetic diversity
Wright, G. D. (2007) · Nature Reviews Microbiology · doi:10.1038/nrmicro1614 · Cited by 1,365
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
Mann, B. S., Johnson, J. R., Cohen, M. H., Justice, R., & Pazdur, R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-10-1247 · Cited by 1,365
Isolating "Uncultivable" Microorganisms in Pure Culture in a Simulated Natural Environment
Kaeberlein, T., Lewis, K., & Epstein, S. S. (2002) · Science · doi:10.1126/science.1070633 · Cited by 1,237
DNA gyrase: an enzyme that introduces superhelical turns into DNA.
Gellert, M., Mizuuchi, K., O'Dea, M. H., & Nash, H. A. (1976) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.73.11.3872 · Cited by 1,204
Quinolone resistance from a transferable plasmid
Martínez-Martínez, L., Pascual, A., & Jacoby, G. A. (1998) · The Lancet · doi:10.1016/s0140-6736(97)07322-4 · Cited by 1,100
Multidrug efflux pumps of gram-negative bacteria
Nikaido, H. (1996) · Journal of Bacteriology · doi:10.1128/jb.178.20.5853-5859.1996 · Cited by 1,082
Gold, H. S., & Moellering, R. C. (1996) · New England Journal of Medicine · doi:10.1056/nejm199611073351907 · Cited by 1,070
A Common Mechanism Underlying Promiscuous Inhibitors from Virtual and High-Throughput Screening
McGovern, S. L., Caselli, E., Grigorieff, N., & Shoichet, B. K. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm010533y · Cited by 1,042
Sreevatsan, S., Pan, X., Stockbauer, K. E., Connell, N. D., Kreiswirth, B. N., Whittam, T. S., & Musser, J. M. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.18.9869 · Cited by 1,024
Triclosan targets lipid synthesis
McMurry, L. M., Oethinger, M., & Levy, S. B. (1998) · Nature · doi:10.1038/28970 · Cited by 1,019
Physiochemical drug properties associated with in vivo toxicological outcomes
Hughes, J. D., Blagg, J., Price, D. A., Bailey, S., DeCrescenzo, G. A., Devraj, R. V., Ellsworth, E., Fobian, Y. M., Gibbs, M. E., Gilles, R. W., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.071 · Cited by 946
The porin and the permeating antibiotic: a selective diffusion barrier in Gram-negative bacteria
Pagès, J.-M., James, C. E., & Winterhalter, M. (2008) · Nature Reviews Microbiology · doi:10.1038/nrmicro1994 · Cited by 939
Trends in antimicrobial drug development: Implications for the future
Spellberg, B., Powers, J. H., Brass, E. P., Miller, L. G., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/420937 · Cited by 867
The biological cost of antibiotic resistance
Andersson, D. I., & Levin, B. R. (1999) · Current Opinion in Microbiology · doi:10.1016/s1369-5274(99)00005-3 · Cited by 867
Oppenheimer, N. J., & James, T. L. (1989) · Academic Press eBooks · Cited by 820
Platensimycin is a selective FabF inhibitor with potent antibiotic properties
Wang, J., Soisson, S. M., Young, K., Shoop, W., Kodali, S., Galgoci, A., Painter, R., Parthasarathy, G., Tang, Y. S., Cummings, R., et al. (2006) · Nature · doi:10.1038/nature04784 · Cited by 812
Self-citationTHE MECHANISM OF ACTION OF FOSFOMYCIN (PHOSPHONOMYCIN)
Kahan, F. M., Kahan, J. S., Cassidy, P. J., & Kropp, H. (1974) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1974.tb43277.x · Cited by 777
Crystal structures of a multidrug transporter reveal a functionally rotating mechanism
Murakami, S., Nakashima, R., Yamashita, E., Matsumoto, T., & Yamaguchi, A. (2006) · Nature · doi:10.1038/nature05076 · Cited by 773
Where will new antibiotics come from?
Walsh, C. (2003) · Nature Reviews Microbiology · doi:10.1038/nrmicro727 · Cited by 755
Long, K. S., Poehlsgaard, J., Kehrenberg, C., Schwarz, S., & Vester, B. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00131-06 · Cited by 708
The Natural Functions of Secondary Metabolites
Demain, A. L., & Fang, A. (2000) · Advances in Biochemical Engineering/Biotechnology · doi:10.1007/3-540-44964-7_1 · Cited by 707
Lipid II as a target for antibiotics
Breukink, E., & de Kruijff, B. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2004 · Cited by 701
Mutation Frequencies and Antibiotic Resistance
Martinez, J. L., & Baquero, F. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.7.1771-1777.2000 · Cited by 694
Physicochemical Properties of Antibacterial Compounds: Implications for Drug Discovery
O’Shea, R., & Moser, H. E. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm700967e · Cited by 689
Resistance to Antibiotics Mediated by Target Alterations
Spratt, B. G. (1994) · Science · doi:10.1126/science.8153626 · Cited by 674
Viracept (Nelfinavir Mesylate, AG1343): A Potent, Orally Bioavailable Inhibitor of HIV-1 Protease
Kaldor, S. W., Kalish, V. J., Davies, J. F., Shetty, B. V., Fritz, J. E., Appelt, K., Burgess, J. A., Campanale, K. M., Chirgadze, N. Y., Clawson, D. K., et al. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm9704098 · Cited by 618
A Specific Mechanism of Nonspecific Inhibition
McGovern, S. L., Helfand, B. T., Feng, B., & Shoichet, B. K. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030266r · Cited by 598
Phosphonomycin, a New Antibiotic Produced by Strains of Streptomyces
Hendlin, D., Stapley, E. O., Jackson, M., Wallick, H., Miller, A. K., Wolf, F. J., Miller, T. W., Chaiet, L., Kahan, F. M., Foltz, E. L., et al. (1969) · Science · doi:10.1126/science.166.3901.122 · Cited by 593
Brickner, S. J., Hutchinson, D. K., Barbachyn, M. R., Manninen, P. R., Ulanowicz, D. A., Garmon, S. A., Grega, K. C., Hendges, S. K., Toops, D. S., Ford, C. W., et al. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm9509556 · Cited by 582
Mechanisms of RND multidrug efflux pumps
Nikaido, H., & Takatsuka, Y. (2009) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2008.10.004 · Cited by 555
Peptidomimetic Antibiotics Target Outer-Membrane Biogenesis in Pseudomonas aeruginosa
Srinivas, N., Jetter, P., Ueberbacher, B. J., Werneburg, M., Zerbe, K., Steinmann, J., Van der Meijden, B., Bernardini, F., Lederer, A., Dias, R. L. A., et al. (2010) · Science · doi:10.1126/science.1182749 · Cited by 554
Plectasin, a Fungal Defensin, Targets the Bacterial Cell Wall Precursor Lipid II
Schneider, T., Kruse, T., Wimmer, R., Wiedemann, I., Sass, V., Pag, U., Jansen, A., Nielsen, A. K., Mygind, P. H., Raventós, D. S., et al. (2010) · Science · doi:10.1126/science.1185723 · Cited by 550
Trimethoprim and sulfonamide resistance.
Huovinen, P., Sundström, L., Swedberg, G., & Sköld, O. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.2.279 · Cited by 523
Curcumin inhibits FtsZ assembly: an attractive mechanism for its antibacterial activity
Rai, D., Singh, J. K., Roy, N., & Panda, D. (2008) · Biochemical Journal · doi:10.1042/bj20070891 · Cited by 523
Pursuing the leadlikeness concept in pharmaceutical research
Hann, M. M., & Oprea, T. I. (2004) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2004.04.003 · Cited by 515
The role of natural environments in the evolution of resistance traits in pathogenic bacteria
Martinez, J. L. (2009) · Proceedings of the Royal Society B: Biological Sciences · doi:10.1098/rspb.2009.0320 · Cited by 513
Why is big Pharma getting out of antibacterial drug discovery?
Projan, S. J. (2003) · Current Opinion in Microbiology · doi:10.1016/j.mib.2003.08.003 · Cited by 503
Extraction of a Highly Potent Penicillin Inactivator from Penicillin Resistant Staphylococci
Kirby, W. M. M. (1944) · Science · doi:10.1126/science.99.2579.452 · Cited by 502
Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori
Versalovic, J., Shortridge, D., Kibler, K., Griffy, M. V., Beyer, J., Flamm, R. K., Tanaka, S. K., Graham, D. Y., & Go, M. F. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.2.477 · Cited by 501
A genome‐wide strategy for the identification of essential genes in Staphylococcus aureus
Forsyth, R. A., Haselbeck, R. J., Ohlsen, K. L., Yamamoto, R. T., Xu, H., Trawick, J. D., Wall, D., Wang, L., Brown‐Driver, V., Froelich, J. M., et al. (2002) · Molecular Microbiology · doi:10.1046/j.1365-2958.2002.02832.x · Cited by 487
Determining Mutation Rates in Bacterial Populations
Rosche, W. A., & Foster, P. L. (2000) · Methods · doi:10.1006/meth.1999.0901 · Cited by 482
The biological cost of mutational antibiotic resistance: any practical conclusions?
Andersson, D. I. (2006) · Current Opinion in Microbiology · doi:10.1016/j.mib.2006.07.002 · Cited by 472
Takahashi, S., Kuzuyama, T., Watanabe, H., & Seto, H. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.17.9879 · Cited by 469
TRIMETHOPRIM, A SULPHONAMIDE POTENTIATOR
BUSHBY, S. R. M., & HITCHINGS, G. H. (1968) · British Journal of Pharmacology and Chemotherapy · doi:10.1111/j.1476-5381.1968.tb00475.x · Cited by 466
Multidrug resistance mechanisms: drug efflux across two membranes
Zgurskaya, H. I., & Nikaido, H. (2000) · Molecular Microbiology · doi:10.1046/j.1365-2958.2000.01926.x · Cited by 466
Lomovskaya, O., & Bostian, K. A. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.12.008 · Cited by 460
An Inhibitor of FtsZ with Potent and Selective Anti-Staphylococcal Activity
Haydon, D. J., Stokes, N. R., Ure, R., Galbraith, G., Bennett, J. M., Brown, D. R., Baker, P. J., Barynin, V. V., Rice, D. W., Sedelnikova, S. E., et al. (2008) · Science · doi:10.1126/science.1159961 · Cited by 452
Effects of Environment on Compensatory Mutations to Ameliorate Costs of Antibiotic Resistance
Björkman, J., Nagaev, I., Berg, O. G., Hughes, D., & Andersson, D. I. (2000) · Science · doi:10.1126/science.287.5457.1479 · Cited by 452
Koller, W. C., Lyons, K., Pahwa, R., & Sf, S. W. (2002) · Cited by 421
The emergence of antibiotic resistance by mutation
Woodford, N., & Ellington, M. J. (2007) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2006.01492.x · Cited by 417
Glycopeptide resistance in enterococci
ARTHUR, M., REYNOLDS, P., & COURVALIN, P. (1996) · Trends in Microbiology · doi:10.1016/0966-842x(96)10063-9 · Cited by 414
Evolution of Drug Resistance in Mycobacterium tuberculosis : Clinical and Molecular Perspective
Gillespie, S. H. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.2.267-274.2002 · Cited by 412
Antibacterial Agents That Inhibit Lipid A Biosynthesis
Onishi, H. R., Pelak, B. A., Gerckens, L. S., Silver, L. L., Kahan, F. M., Chen, M.-H., Patchett, A. A., Galloway, S. M., Hyland, S. A., Anderson, M. S., et al. (1996) · Science · doi:10.1126/science.274.5289.980 · Cited by 410
Self-citationProteomic Approach to Understanding Antibiotic Action
Bandow, J. E., Brötz, H., Leichert, L. I. O., Labischinski, H., & Hecker, M. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.3.948-955.2003 · Cited by 391
Kuzuyama, T., Shimizu, T., Takahashi, S., & Seto, H. (1998) · Tetrahedron Letters · doi:10.1016/s0040-4039(98)01755-9 · Cited by 381
Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties
Wang, J., Kodali, S., Lee, S. H., Galgoci, A., Painter, R., Dorso, K., Racine, F., Motyl, M., Hernandez, L., Tinney, E., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700746104 · Cited by 381
Nonleadlikeness and leadlikeness in biochemical screening
Rishton, G. M. (2003) · Drug Discovery Today · doi:10.1016/s1359644602025722 · Cited by 381
Topoisomerase IV is a target of quinolones in Escherichia coli.
Khodursky, A. B., Zechiedrich, E. L., & Cozzarelli, N. R. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.25.11801 · Cited by 378
Ferrero, L., Cameron, B., Manse, B., Lagneaux, D., Crouzet, J., Famechon, A., & Blanche, F. (1994) · Molecular Microbiology · doi:10.1111/j.1365-2958.1994.tb00458.x · Cited by 378
Inhibition of human immunodeficiency virus type-1 integrase by curcumin
Mazumder, A., Raghavan, K., Weinstein, J., Kohn, K. W., & Pommier, Y. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)98514-a · Cited by 375
Generating Diverse Skeletons of Small Molecules Combinatorially
Burke, M. D., Berger, E. M., & Schreiber, S. L. (2003) · Science · doi:10.1126/science.1089946 · Cited by 375
Global tuberculosis drug development pipeline: the need and the reality
Ma, Z., Lienhardt, C., McIlleron, H., Nunn, A. J., & Wang, X. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60359-9 · Cited by 374
Reactive compounds and in vitro false positives in HTS
Rishton, G. M. (1997) · Drug Discovery Today · doi:10.1016/s1359-6446(97)01083-0 · Cited by 351
Functional classification of drugs by properties of their pairwise interactions
Yeh, P., Tschumi, A. I., & Kishony, R. (2006) · Nature Genetics · doi:10.1038/ng1755 · Cited by 350
Schwarz, S., Werckenthin, C., & Kehrenberg, C. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.9.2530-2533.2000 · Cited by 341
Inhibition of β-Ketoacyl-Acyl Carrier Protein Synthases by Thiolactomycin and Cerulenin
Price, A. C., Choi, K.-H., Heath, R. J., Li, Z., White, S. W., & Rock, C. O. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m007101200 · Cited by 335
Dihydrofolate reductase inhibitors as antibacterial agents
Hawser, S., Lociuro, S., & Islam, K. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.10.052 · Cited by 335
Proliferation of mutators in A cell population
Mao, E. F., Lane, L., Lee, J., & Miller, J. H. (1997) · Journal of Bacteriology · doi:10.1128/jb.179.2.417-422.1997 · Cited by 325
Predicting antibiotic resistance
Martínez, J. L., Baquero, F., & Andersson, D. I. (2007) · Nature Reviews Microbiology · doi:10.1038/nrmicro1796 · Cited by 317
Type II fatty acid synthesis is not a suitable antibiotic target for Gram-positive pathogens
Brinster, S., Lamberet, G., Staels, B., Trieu-Cuot, P., Gruss, A., & Poyart, C. (2009) · Nature · doi:10.1038/nature07772 · Cited by 317
Multi-targeting by monotherapeutic antibacterials
Silver, L. L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2202 · Cited by 311
Self-citationTransferable vancomycin and teicoplanin resistance in Enterococcus faecium
Leclercq, R., Derlot, E., Weber, M., Duval, J., & Courvalin, P. (1989) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.33.1.10 · Cited by 306
Actinonin, a Naturally Occurring Antibacterial Agent, Is a Potent Deformylase Inhibitor
Chen, D. Z., Patel, D. V., Hackbarth, C. J., Wang, W., Dreyer, G. B., Young, D. C., Margolis, P. S., Wu, C., Ni, Z.-J., Trias, J., et al. (2000) · Biochemistry · doi:10.1021/bi992245y · Cited by 298
Mode of Action of Fluoroquinolones
Hooper, D. C. (1999) · Drugs · doi:10.2165/00003495-199958002-00002 · Cited by 290
Denome, S. A., Elf, P. K., Henderson, T. A., Nelson, D. E., & Young, K. D. (1999) · Journal of Bacteriology · doi:10.1128/jb.181.13.3981-3993.1999 · Cited by 288
Expanding the soil antibiotic resistome: exploring environmental diversity
D’Costa, V. M., Griffiths, E., & Wright, G. D. (2007) · Current Opinion in Microbiology · doi:10.1016/j.mib.2007.08.009 · Cited by 287
A triclosan-resistant bacterial enzyme
Heath, R. J., & Rock, C. O. (2000) · Nature · doi:10.1038/35018162 · Cited by 284
The Biosynthesis of Folic Acid
Brown, G. M. (1962) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)93957-8 · Cited by 274
Structure, function and inhibition of RND efflux pumps in Gram-negative bacteria: an update
Blair, J. M., & Piddock, L. J. (2009) · Current Opinion in Microbiology · doi:10.1016/j.mib.2009.07.003 · Cited by 266
Cell-division inhibitors: new insights for future antibiotics
Lock, R. L., & Harry, E. J. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2510 · Cited by 263
Gene Dosage and Linezolid Resistance in Enterococcus faecium and Enterococcus faecalis
Marshall, S. H., Donskey, C. J., Hutton-Thomas, R., Salata, R. A., & Rice, L. B. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.10.3334-3336.2002 · Cited by 263
An oldie but a goodie – cell wall biosynthesis as antibiotic target pathway
Schneider, T., & Sahl, H.-G. (2010) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2009.10.005 · Cited by 261
Are antibiotics naturally antibiotics?
Davies, J. (2006) · Journal of Industrial Microbiology & Biotechnology · doi:10.1007/s10295-006-0112-5 · Cited by 259
Biological cost and compensatory evolution in fusidic acid‐resistant Staphylococcus aureus
Nagaev, I., Björkman, J., Andersson, D. I., & Hughes, D. (2001) · Molecular Microbiology · doi:10.1046/j.1365-2958.2001.02389.x · Cited by 257
New Drugs against Tuberculosis: Problems, Progress, and Evaluation of Agents in Clinical Development
van den Boogaard, J., Kibiki, G. S., Kisanga, E. R., Boeree, M. J., & Aarnoutse, R. E. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00749-08 · Cited by 257
Inhibitors of FabI, an Enzyme Drug Target in the Bacterial Fatty Acid Biosynthesis Pathway
Lu, H., & Tonge, P. J. (2008) · Accounts of Chemical Research · doi:10.1021/ar700156e · Cited by 254
Discovery and development of new antibiotics: the problem of antibiotic resistance
Silver, L. L., & Bostian, K. A. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.3.377 · Cited by 253
Self-citationNitazoxanide for the Treatment of Clostridium difficile Colitis
Musher, D. M., Logan, N., Hamill, R. J., DuPont, H. L., Lentnek, A., Gupta, A., & Rossignol, J.-F. (2006) · Clinical Infectious Diseases · doi:10.1086/506351 · Cited by 249
Mazel, D., Pochet, S., & Marlière, P. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06335.x · Cited by 246
Antibacterial discovery and development—the failure of success?
Fernandes, P. (2006) · Nature Biotechnology · doi:10.1038/nbt1206-1497 · Cited by 246
Baltz, R. H. (2006) · Journal of Industrial Microbiology & Biotechnology · doi:10.1007/s10295-005-0077-9 · Cited by 246
Hoffman, P. S., Sisson, G., Croxen, M. A., Welch, K., Harman, W. D., Cremades, N., & Morash, M. G. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01159-06 · Cited by 244
Biological Costs and Mechanisms of Fosfomycin Resistance in Escherichia coli
Nilsson, A. I., Berg, O. G., Aspevall, O., Kahlmeter, G., & Andersson, D. I. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.9.2850-2858.2003 · Cited by 241
Inhibitors of efflux pumps in Gram-negative bacteria
Pagès, J.-M., Masi, M., & Barbe, J. (2005) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2005.06.006 · Cited by 238
Sanguinarine Blocks Cytokinesis in Bacteria by Inhibiting FtsZ Assembly and Bundling
Beuria, T. K., Santra, M. K., & Panda, D. (2005) · Biochemistry · doi:10.1021/bi050767+ · Cited by 236
ANTAGONISTS OF NUCLEIC ACID DERIVATIVES
Hitchings, G. H., Falco, E. A., Vanderwerff, H., Russell, P. B., & Elion, G. B. (1952) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)44808-9 · Cited by 235
Molecular Mechanisms of Multiple Drug Resistance in Clinical Isolates of Mycobacterium tuberculosis
Morris, S., Bai, G. H., Suffys, P., Portillo-Gomez, L., Fairchok, M., & Rouse, D. (1995) · Journal of Infectious Diseases · doi:10.1093/infdis/171.4.954 · Cited by 231
Antibiotic Activity and Characterization of BB-3497, a Novel Peptide Deformylase Inhibitor
Clements, J. M., Beckett, R. P., Brown, A., Catlin, G., Lobell, M., Palan, S., Thomas, W., Whittaker, M., Wood, S., Salama, S., et al. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.2.563-570.2001 · Cited by 230
Ruiz, N. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808352105 · Cited by 230
Compensatory adaptation to the deleterious effect of antibiotic resistance in Salmonella typhimurium
Maisnier‐Patin, S., Berg, O. G., Liljas, L., & Andersson, D. I. (2002) · Molecular Microbiology · doi:10.1046/j.1365-2958.2002.03173.x · Cited by 228
Aubry-Damon, H., Soussy, C.-J., & Courvalin, P. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.10.2590 · Cited by 225
Quantifying biogenic bias in screening libraries
Hert, J., Irwin, J. J., Laggner, C., Keiser, M. J., & Shoichet, B. K. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.180 · Cited by 222
Freiberg, C., Brunner, N. A., Schiffer, G., Lampe, T., Pohlmann, J., Brands, M., Raabe, M., Häbich, D., & Ziegelbauer, K. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402989200 · Cited by 218
Penicillin-Binding Proteins of Gram-Negative Bacteria
Spratt, B. G., & Cromie, K. D. (1988) · Clinical Infectious Diseases · doi:10.1093/clinids/10.4.699 · Cited by 217
Margalit, D. N., Romberg, L., Mets, R. B., Hebert, A. M., Mitchison, T. J., Kirschner, M. W., & RayChaudhuri, D. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404439101 · Cited by 206
Adamek, R. (1998) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(97)00110-x · Cited by 202
Discovery of FabH/FabF Inhibitors from Natural Products
Young, K., Jayasuriya, H., Ondeyka, J. G., Herath, K., Zhang, C., Kodali, S., Galgoci, A., Painter, R., Brown-Driver, V., Yamamoto, R., et al. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.2.519-526.2006 · Cited by 202
Self-citationZhu, L., Lin, J., Ma, J., Cronan, J. E., & Wang, H. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01152-09 · Cited by 201
Antibacterial Activities and Characterization of Novel Inhibitors of LpxC
Clements, J. M., Coignard, F., Johnson, I., Chandler, S., Palan, S., Waller, A., Wijkmans, J., & Hunter, M. G. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.6.1793-1799.2002 · Cited by 201
Wang, J., Galgoci, A., Kodali, S., Herath, K. B., Jayasuriya, H., Dorso, K., Vicente, F., González, A., Cully, D., Bramhill, D., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m307625200 · Cited by 200
Takatsuka, Y., Chen, C., & Nikaido, H. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1001460107 · Cited by 196
Kim, D. H., Lees, W. J., Kempsell, K. E., Lane, W. S., Duncan, K., & Walsh, C. T. (1996) · Biochemistry · doi:10.1021/bi952937w · Cited by 192
The Enoyl-[acyl-carrier-protein] Reductases FabI and FabL fromBacillus subtilis
Heath, R. J., Su, N., Murphy, C. K., & Rock, C. O. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m005611200 · Cited by 184
Schneider, T., Gries, K., Josten, M., Wiedemann, I., Pelzer, S., Labischinski, H., & Sahl, H.-G. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01040-08 · Cited by 181
A predictive model for the selective accumulation of chemicals in tumor cells
Trapp, S., & Horobin, R. W. (2005) · European Biophysics Journal · doi:10.1007/s00249-005-0472-1 · Cited by 180
OISHI, H., NOTO, T., SASAKI, H., SUZUKI, K., HAYASHI, T., OKAZAKI, H., ANDO, K., & SAWADA, M. (1982) · The Journal of Antibiotics · doi:10.7164/antibiotics.35.391 · Cited by 179
Horobin, R. W., Trapp, S., & Weissig, V. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.05.040 · Cited by 172
Curcumin Inhibits Glyoxalase 1—A Possible Link to Its Anti-Inflammatory and Anti-Tumor Activity
Santel, T., Pflug, G., Hemdan, N. Y. A., Schäfer, A., Hollenbach, M., Buchold, M., Hintersdorf, A., Lindner, I., Otto, A., Bigl, M., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003508 · Cited by 170
Rajeswari, A., & Sabesan, M. (2008) · Inflammopharmacology · doi:10.1007/s10787-007-1614-0 · Cited by 170
Discovery of a Novel and Potent Class of FabI-Directed Antibacterial Agents
Payne, D. J., Miller, W. H., Berry, V., Brosky, J., Burgess, W. J., Chen, E., DeWolf, W. E., Fosberry, A. P., Greenwood, R., Head, M. S., et al. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.10.3118-3124.2002 · Cited by 170
Diversity in enoyl-acyl carrier protein reductases
Massengo-Tiassé, R. P., & Cronan, J. E. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-8704-7 · Cited by 164
Cassell, G. H. (2001) · JAMA · doi:10.1001/jama.285.5.601 · Cited by 162
Reducing the fitness cost of antibiotic resistance by amplification of initiator tRNA genes
Nilsson, A. I., Zorzet, A., Kanth, A., Dahlström, S., Berg, O. G., & Andersson, D. I. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602171103 · Cited by 159
A class of selective antibacterials derived from a protein kinase inhibitor pharmacophore
Miller, J. R., Dunham, S., Mochalkin, I., Banotai, C., Bowman, M., Buist, S., Dunkle, B., Hanna, D., Harwood, H. J., Huband, M. D., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811275106 · Cited by 159
Bellon, S., Parsons, J. D., Wei, Y., Hayakawa, K., Swenson, L. L., Charifson, P. S., Lippke, J. A., Aldape, R., & Gross, C. H. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.5.1856-1864.2004 · Cited by 159
Quantitative modeling of selective lysosomal targeting for drug design
Trapp, S., Rosania, G. R., Horobin, R. W., & Kornhuber, J. (2008) · European Biophysics Journal · doi:10.1007/s00249-008-0338-4 · Cited by 158
Essentiality of FASII pathway for Staphylococcus aureus
Balemans, W., Lounis, N., Gilissen, R., Guillemont, J., Simmen, K., Andries, K., & Koul, A. (2010) · Nature · doi:10.1038/nature08667 · Cited by 156
Mohan, S., Kelly, T. M., Eveland, S. S., Raetz, C. R. H., & Anderson, M. S. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)30075-2 · Cited by 155
McClerren, A. L., Endsley, S., Bowman, J. L., Andersen, N. H., Guan, Z., Rudolph, J., & Raetz, C. R. H. (2005) · Biochemistry · doi:10.1021/bi0518186 · Cited by 155
Newer antibacterial drugs for a new century
Devasahayam, G., Scheld, W. M., & Hoffman, P. S. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903505092 · Cited by 155
Exploiting current understanding of antibiotic action for discovery of new drugs
Chopra, I., Hesse, L., & O’Neill, A. J. (2002) · Journal of Applied Microbiology · doi:10.1046/j.1365-2672.92.5s1.13.x · Cited by 154
Genetic strategies for antibacterial drug discovery
Miesel, L., Greene, J. R., & Black, T. A. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1086 · Cited by 152
The bacterial envelope as a target for novel anti-MRSA antibiotics
Françoise Van Bambeke, A., Mingeot‐Leclercq, M., Struelens, M. J., & Tulkens, P. M. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.12.004 · Cited by 149
Tam, V. H., Chang, K., Abdelraouf, K., Brioso, C. G., Ameka, M., McCaskey, L. A., Weston, J. S., Caeiro, J., & Garey, K. W. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01446-09 · Cited by 147
Reduction of the fitness burden of quinolone resistance in Pseudomonas aeruginosa
Kugelberg, E., Löfmark, S., Wretlind, B., & Andersson, D. I. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh505 · Cited by 147
Black, M. T., Stachyra, T., Platel, D., Girard, A.-M., Claudon, M., Bruneau, J., & Miossec, C. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00496-08 · Cited by 146
Lipophilicity Profiles of Ampholytes
Pagliara, A., Carrupt, P., Caron, G., Gaillard, P., & Testa, B. (1997) · Chemical Reviews · doi:10.1021/cr9601019 · Cited by 145
Predictable and unpredictable evolution of antibiotic resistance
Courvalin, P. M. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2008.01940.x · Cited by 145
Structure-based discovery of antibacterial drugs
Simmons, K. J., Chopra, I., & Fishwick, C. W. G. (2010) · Nature Reviews Microbiology · doi:10.1038/nrmicro2349 · Cited by 145
Trends in antimicrobial drug development: Implications for the future
Sergio Mella, M. (2005) · Revista chilena de infectología · doi:10.4067/s0716-10182005000200011 · Cited by 144
Novel Whole-Cell Antibiotic Biosensors for Compound Discovery
Urban, A., Eckermann, S., Fast, B., Metzger, S., Gehling, M., Ziegelbauer, K. B., Rübsamen‐Waigmann, H., & Freiberg, C. (2007) · Applied and Environmental Microbiology · doi:10.1128/aem.00586-07 · Cited by 142
Jackman, J. E., Raetz, C. R. H., & Fierke, C. A. (1999) · Biochemistry · doi:10.1021/bi982339s · Cited by 140
Bacterial fatty-acid biosynthesis: a genomics-driven target for antibacterial drug discovery
Payne, D. J., Warren, P. V., Holmes, D. J., Ji, Y., & Lonsdale, J. T. (2001) · Drug Discovery Today · doi:10.1016/s1359-6446(01)01774-3 · Cited by 140
OKUHARA, M., Kuroda, Y., Goto, T., Okamoto, M., Terano, H., KOHSAKA, M., AOKI, H., & Imanaka, H. (1980) · The Journal of Antibiotics · doi:10.7164/antibiotics.33.24 · Cited by 140
Exploiting genomics, genetics and chemistry to combat antibiotic resistance
Hughes, D. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1084 · Cited by 139
Penicillin-binding proteins in bacteria
Georgopapadakou, N. H., & Liu, F. Y. (1980) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.18.1.148 · Cited by 139
Structure-Based Virtual Ligand Screening: Recent Success Stories
Villoutreix, B. O., Eudes, R., & Miteva, M. A. (2009) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/138620709789824682 · Cited by 139
The pleuromutilin antibiotics: a new class for human use.
Novak, R., & Shlaes, D. M. (2010) · PubMed · Cited by 135
Fuente, R. D. L., Sonawane, N. D., Arumainayagam, D. C., & Verkman, A. S. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706873 · Cited by 135
How many modes of action should an antibiotic have?
Brötz‐Oesterhelt, H., & Brunner, N. A. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.06.008 · Cited by 133
Vibrio cholerae FabV Defines a New Class of Enoyl-Acyl Carrier Protein Reductase
Massengo-Tiassé, R. P., & Cronan, J. E. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m708171200 · Cited by 129
Nitazoxanide Kills Replicating and Nonreplicating Mycobacterium tuberculosis and Evades Resistance
de Carvalho, L. P. S., Lin, G., Jiang, X., & Nathan, C. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm9010719 · Cited by 129
PARENTI, F., PAGANI, H., & BERETTA, G. (1975) · The Journal of Antibiotics · doi:10.7164/antibiotics.28.247 · Cited by 128
Preclinical evaluation of novel antibacterial agents by microbiological and molecular techniques
O’Neill, A. J., & Chopra, I. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.8.1045 · Cited by 126
Heerding, D. A., Chan, G., DeWolf, W. E., Fosberry, A. P., Janson, C. A., Jaworski, D. D., McManus, E. C., Miller, W. H., Moore, T. D., Payne, D. J., et al. (2001) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00404-8 · Cited by 125
Qin, Z., Zhang, J., Xu, B., Chen, L., Wu, Y., Yang, X., Shen, X., Molin, S., Danchin, A., Jiang, H., et al. (2006) · BMC Microbiology · doi:10.1186/1471-2180-6-96 · Cited by 123
Musher, D. M., Logan, N. D., Mehendiratta, V., Melgarejo, N. A., Garud, S. S., & Hamill, R. J. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl553 · Cited by 123
Human mitochondrial peptide deformylase, a new anticancer target of actinonin-based antibiotics
Lee, M. D., She, Y., Soskis, M. J., Borella, C. P., Gardner, J. R., Hayes, P. A., Dy, B. M., Heaney, M. L., Philips, M. R., Bornmann, W. G., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422269 · Cited by 123
In Vitro Activities of OPT-80 and Comparator Drugs against Intestinal Bacteria
Finegold, S. M., Molitoris, D. R., Väisänen, M., Song, Y., Liu, C., & Bolaňos, M. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.12.4898-4902.2004 · Cited by 122
Huber, J. L., Donald, R. G. K., Lee, S. H., Jarantow, L. W., Salvatore, M. J., Meng, X., Painter, R. E., Onishi, R., Occi, J., Dorso, K., et al. (2009) · Chemistry & Biology · doi:10.1016/j.chembiol.2009.05.012 · Cited by 121
Thiolactomycin, a new antibiotic. III. In vitro antibacterial activity.
NOTO, T., Miyakawa, S., OISHI, H., ENDO, H., & Okazaki, H. (1982) · The Journal of Antibiotics · doi:10.7164/antibiotics.35.401 · Cited by 120
An array of target-specific screening strains for antibacterial discovery
DeVito, J. A., Mills, J. A., Liu, V. G., Agarwal, A., Sizemore, C. F., Yao, Z., Stoughton, D., Cappiello, M. G., Barbosa, M. D. F. S., Foster, L. A., et al. (2002) · Nature Biotechnology · doi:10.1038/nbt0502-478 · Cited by 119
Thiolactomycin, a new antibiotic. IV. Biological properties and chemotherapeutic activity in mice.
Miyakawa, S., SUZUKI, K., NOTO, T., Harada, Y., & Okazaki, H. (1982) · The Journal of Antibiotics · doi:10.7164/antibiotics.35.411 · Cited by 117
Hydroxamates: Relationships between Structure and Plasma Stability
Flipo, M., Charton, J., Hocine, A., Dassonneville, S., Deprez, B. P., & Deprez-Poulain, R. F. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900648x · Cited by 116
Bioaccumulation of Polar and Ionizable Compounds in Plants
Trapp, S. (2009) · Emerging topics in ecotoxicology · doi:10.1007/978-1-4419-0197-2_11 · Cited by 116
Hackbarth, C. J., Chen, D. Z., Lewis, J. G., Clark, K., Mangold, J. B., Cramer, J. A., Margolis, P. S., Wang, W., Koehn, J., Wu, C., et al. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.9.2752-2764.2002 · Cited by 115
Eveland, S. S., Pompliano, D. L., & Anderson, M. S. (1997) · Biochemistry · doi:10.1021/bi9701078 · Cited by 114
Discovery of Aminopyridine-Based Inhibitors of Bacterial Enoyl-ACP Reductase (FabI)
Miller, W. H., Seefeld, M. A., Newlander, K. A., Uzinskas, I. N., Burgess, W. J., Heerding, D. A., Yuan, C. C.-K., Head, M. S., Payne, D. J., Rittenhouse, S. F., et al. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020050+ · Cited by 113
Piddock, L. J. V., Garvey, M. I., Rahman, M. M., & Gibbons, S. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq079 · Cited by 111
Novel inhibitors of bacterial cell wall synthesis
Silver, L. L. (2003) · Current Opinion in Microbiology · doi:10.1016/j.mib.2003.08.004 · Cited by 108
Self-citationIdentification and Characterization of New Inhibitors of the Escherichia coli MurA Enzyme
Baum, E. Z., Montenegro, D. A., Licata, L., et al. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.11.3182-3188.2001 · Cited by 107
The Targets of Currently Used Antibacterial Agents: Lessons for Drug Discovery
Lange, R., Locher, H. H., Wyss, P. C., et al. (2007) · Current Pharmaceutical Design · doi:10.2174/138161207782110408 · Cited by 107
Haydon, D. J., Bennett, J. M., Brown, D., Collins, I., Galbraith, G., Lancett, P., Macdonald, R., Stokes, N. R., Chauhan, P. K., Sutariya, J. K., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm9016366 · Cited by 106
Freiberg, C., Fischer, H. P., & Brunner, N. A. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.2.749-759.2005 · Cited by 105
Screening of natural products for antimicrobial agents
Silver, L. L., & Bostian, K. A. (1990) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf01964283 · Cited by 104
Self-citationA New Class of Bacterial RNA Polymerase Inhibitor Affects Nucleotide Addition
Artsimovitch, I., Chu, C., Lynch, A. S., & Landick, R. C. (2003) · Science · doi:10.1126/science.1087526 · Cited by 103
Jarvest, R. L., Berge, J. M., Berry, V., Boyd, H., Brown, M. J. B., Elder, J. S., Forrest, A. K., Fosberry, A. P., Gentry, D. R., Hibbs, M. J., et al. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm025502x · Cited by 103
Bukanov, N. O., & Berg, D. E. (1994) · Molecular Microbiology · doi:10.1111/j.1365-2958.1994.tb00332.x · Cited by 103
Efflux systems in bacterial pathogens: An opportunity for therapeutic intervention? An industry view
Lynch, A. S. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.10.021 · Cited by 103
Mechanistic Diversity of Fosfomycin Resistance in Pathogenic Microorganisms
Fillgrove, K. L., Pakhomova, S. V., Newcomer, M. E., & Armstrong, R. N. (2003) · Journal of the American Chemical Society · doi:10.1021/ja039307z · Cited by 102
Gomez, L., Hack, M. D., Wu, J., Wiener, J. J. M., Venkatesan, H., Santillán, A., Pippel, D. J., Mani, N. S., Morrow, B. J., Motley, S. T., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.03.003 · Cited by 101
Elongation factor Tu‐targeted antibiotics: Four different structures, two mechanisms of action
Parmeggiani, A., & Nissen, P. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.07.039 · Cited by 98
Li, X., Zolli‐Juran, M., Cechetto, J. D., Daigle, D. M., Wright, G. D., & Brown, E. D. (2004) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.08.014 · Cited by 98
Donald, R. G. K., Skwish, S., Forsyth, A., Anderson, J. W., Zhong, T., Burns, C. M., Lee, S., Meng, X., LoCastro, L., Jarantow, L. W., et al. (2009) · Chemistry & Biology · doi:10.1016/j.chembiol.2009.07.004 · Cited by 97
Hu, Y., Helm, J. S., Chen, L., Ginsberg, C., Gross, B. J., Kraybill, B. C., Tiyanont, K., Fang, X., Wu, T., & Walker, S. (2004) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.02.024 · Cited by 95
Bacterial RNA polymerase: a promising target for the discovery of new antimicrobial agents.
Chopra, I. (2007) · PubMed · Cited by 93
Computational analysis of ligand relationships within target families
Bajorath, J. (2008) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2008.01.044 · Cited by 92
In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile
Swanson, R. N., Hardy, D. J., Shipkowitz, N. L., Hanson, C. W., Ramer, N. C., FERNANDES, P. B., & Clement, J. J. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.6.1108 · Cited by 92
Urgaonkar, S., Pierre, H. S. L., Meir, I., Lund, H., RayChaudhuri, D., & Shaw, J. T. (2005) · Organic Letters · doi:10.1021/ol052269z · Cited by 92
Antibacterial alkoxybenzamide inhibitors of the essential bacterial cell division protein FtsZ
Czaplewski, L. G., Collins, I., Boyd, E. A., Brown, D., East, S. P., Gardiner, M., Fletcher, R., Haydon, D. J., Henstock, V., Ingram, P., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.11.021 · Cited by 91
Research works printed but not linked: 114
- 10.1016/S1044-0305(96)00104-3 · doi:10.1016/s1044-0305(96)00104-3
- 10.1016/j.bmcl.2007.02.056 · doi:10.1016/j.bmcl.2007.02.056
- 10.1021/jm020483c · doi:10.1021/jm020483c
- 10.1016/S0960-894X(00)00073-1 · doi:10.1016/s0960-894x(00)00073-1
- 10.1016/j.bmcl.2005.09.021 · doi:10.1016/j.bmcl.2005.09.021
- 10.1128/AAC.45.4.1058-1064.2001 · doi:10.1128/aac.45.4.1058-1064.2001
- 10.1155/2010/315056 · doi:10.1155/2010/315056
- Baltz, R. H. 2005. Antibiotic discovery from Actinomycetes: will a renaissance follow the decline and fall. SIM News 55 : 186-196.
- 10.1021/bi900167q · doi:10.1021/bi900167q
- 10.1021/bi6025165 · doi:10.1021/bi6025165
- 10.1128/AAC.46.4.943-946.2002 · DOI
- 10.1128/AAC.50.1.230-236.2006 · doi:10.1128/aac.50.1.230-236.2006
- 10.1128/AAC.00845-07 · doi:10.1128/aac.00845-07
- 10.1111/j.1574-6968.1988.tb13933.x · doi:10.1111/j.1574-6968.1988.tb13933.x
- 10.1016/0006-291X(86)90452-3 · doi:10.1016/0006-291x(86)90452-3
- 10.1021/bi050767 · doi:10.1021/bi050767
- 10.1016/j.coph.2008.04.009 · doi:10.1016/j.coph.2008.04.009
- 10.2174/092986707780831168 · doi:10.2174/092986707780831168
- 10.1016/S0960-894X(02)01076-4 · doi:10.1016/s0960-894x(02)01076-4
- Brown D. W. 2010. The evolution of a fosfomycin resistance enzyme FosA from P. aeruginosa and the development of a high throughput screen for the discovery of bioactive inhibitors. Ph.D. thesis. Vanderbilt University Nashville TN.
- 10.1128/jb.171.7.4071-4072.1989 · doi:10.1128/jb.171.7.4071-4072.1989
- 10.1021/jm800318d · doi:10.1021/jm800318d
- 10.2174/187152109787047805 · doi:10.2174/187152109787047805
- 10.1006/jmbi.1996.0274 · doi:10.1006/jmbi.1996.0274
- 10.1128/AAC.48.1.250-261.2004 · doi:10.1128/aac.48.1.250-261.2004
- Chopra, I. 2000. New drugs for the superbugs. Microbiol. Today 27 : 4-6.
- 10.1021/jm00010a027 · doi:10.1021/jm00010a027
- 10.1517/13543770902766829 · doi:10.1517/13543770902766829
- 10.7164/antibiotics.40.761 · doi:10.7164/antibiotics.40.761
- 10.1021/jm020901d · doi:10.1021/jm020901d
- Drlica, K. 2001. A strategy for fighting antibiotic resistance. ASM News 67 : 27-33.
- 10.1086/499046 · DOI
- 10.1016/j.bmcl.2008.11.102 · doi:10.1016/j.bmcl.2008.11.102
- 10.1016/j.bbapap.2003.11.006 · doi:10.1016/j.bbapap.2003.11.006
- Elespuru, R. K., and R. J. White. 1983. Biochemical prophage induction assay: a rapid test for antitumor agents that interact with DNA. Cancer Res. 43 : 2819-2830.
- 10.1074/jbc.M414412200 · doi:10.1074/jbc.m414412200
- 10.1128/AAC.49.9.3715-3723.2005 · doi:10.1128/aac.49.9.3715-3723.2005
- Evdokimov, A., M. Pokross, R. L. Walter, M. Mekel, B. L. Barnett, J. Amburgey, W. L. Seibel, S. J. Soper, J. F. Djung, N. Fairweather, C. Diven, V. Rastogi, L. Grinius, C. Klanke, R. Siehnel, T. Twinem, R. Andrews, and A. Curnow. 2007. Serendipitous discovery of novel bacterial methionine aminopeptidase inhibitors. Proteins 66 : 538-546. · doi:10.1002/prot.21207
- 10.1128/AAC.50.4.1136-1142.2006 · doi:10.1128/aac.50.4.1136-1142.2006
- 10.1016/S0960-894X(98)00285-6 · doi:10.1016/s0960-894x(98)00285-6
- 10.1016/j.bmcl.2008.11.113 · doi:10.1016/j.bmcl.2008.11.113
- 10.1128/jb.88.4.1112-1118.1964 · doi:10.1128/jb.88.4.1112-1118.1964
- 10.1128/AAC.00275-08 · doi:10.1128/aac.00275-08
- 10.1128/AAC.00596-06 · doi:10.1128/aac.00596-06
- 10.1128/AAC.50.1.401-402.2006 · doi:10.1128/aac.50.1.401-402.2006
- Guay, D. R. 2007. Drug forecast—the peptide deformylase inhibitors as antibacterial agents. Ther. Clin. Risk Manage. 3 : 513-525.
- 10.1128/AAC.49.8.3178-3181.2005 · doi:10.1128/aac.49.8.3178-3181.2005
- 10.1007/BF01709702 · doi:10.1007/bf01709702
- 10.1128/AAC.22.4.662 · doi:10.1128/aac.22.4.662
- 10.1021/jm050920y · doi:10.1021/jm050920y
- 10.1128/AAC.01321-06 · doi:10.1128/aac.01321-06
- 10.1016/S0968-0896(03)00083-X · doi:10.1016/s0968-0896(03)00083-x
- 10.1128/AAC.49.1.131-136.2005 · doi:10.1128/aac.49.1.131-136.2005
- 10.1128/AAC.01254-06 · doi:10.1128/aac.01254-06
- 10.1038/nbt1206-1529 · doi:10.1038/nbt1206-1529
- 10.1001/archinte.1956.00250250007001 · doi:10.1001/archinte.1956.00250250007001
- Kitamoto, O., N. Kasai, K. Fukuya, and A. Kawashima. 1956. Drug sensitivity of the Shigella strains isolated in 1955. J. Jpn. Assoc. Infect. Dis. 30 : 403-404.
- 10.1128/AAC.40.8.1768 · doi:10.1128/aac.40.8.1768
- 10.2174/138161207781368828 · doi:10.2174/138161207781368828
- 10.1128/AAC.49.3.987-995.2005 · DOI
- 10.1016/j.bmcl.2005.03.058 · DOI
- 10.1248/bpb.32.2061 · doi:10.1248/bpb.32.2061
- 10.1021/bi100523c · doi:10.1021/bi100523c
- Leeds, J. A., and C. R. Dean. 2006. Peptide deformylase as an antibacterial target: a critical assessment. Curr. Opin. Pharmacol. 8 : 8.
- 10.1128/AAC.00073-07 · doi:10.1128/aac.00073-07
- 10.1007/BF00341730 · doi:10.1007/bf00341730
- 10.1128/jb.109.1.326-335.1972 · doi:10.1128/jb.109.1.326-335.1972
- 10.1128/jb.110.1.35-40.1972 · doi:10.1128/jb.110.1.35-40.1972
- 10.1128/jb.110.1.41-46.1972 · doi:10.1128/jb.110.1.41-46.1972
- 10.1128/jb.113.1.96-104.1973 · doi:10.1128/jb.113.1.96-104.1973
- 10.1128/AAC.50.4.1228-1237.2006 · doi:10.1128/aac.50.4.1228-1237.2006
- 10.1128/AAC.42.11.2836 · doi:10.1128/aac.42.11.2836
- 10.1128/AAC.18.2.215 · doi:10.1128/aac.18.2.215
- Miller, D. J., S. M. Hammond, D. Anderluzzi, and T. D. Bugg. 1998. Aminoalkylphosphinate inhibitors of d-Ala-d-Ala adding enzyme. J. Chem. Soc. Perkin 1 1 : 131-142.
- Miller, M. 1995. Aminoglycoside transport, p. 175-219. In N. Georgopapdakou (ed.), Drug transport in antimicrobial and anticancer chemotherapy. Marcel Dekker, Inc., New York, NY.
- 10.1021/jm020050 · doi:10.1021/jm020050
- 10.1016/j.bmcl.2004.01.014 · doi:10.1016/j.bmcl.2004.01.014
- 10.1093/jac/dkn261 · doi:10.1093/jac/dkn261
- 10.1016/j.exppara.2007.06.008 · doi:10.1016/j.exppara.2007.06.008
- 10.2174/092986707781368414 · doi:10.2174/092986707781368414
- Oiwa, R. 1992. Antibacterial agents, p. 1-29. In S. Omura (ed.), The search for bioactive compounds from microorganisms. Springer-Verlag, New York, NY.
- 10.1128/AAC.45.1.1599-1600.2001 · doi:10.1128/aac.45.1.1599-1600.2001
- 10.1534/genetics.109.113514 · doi:10.1534/genetics.109.113514
- 10.1016/j.bmcl.2008.02.009 · doi:10.1016/j.bmcl.2008.02.009
- 10.1016/j.bmcl.2008.10.040 · doi:10.1016/j.bmcl.2008.10.040
- 10.1111/j.1465-0691.2004.1006.x · doi:10.1111/j.1465-0691.2004.1006.x
- 10.1128/AAC.48.12.4835-4842.2004 · DOI
- 10.1016/S0960-894X(01)00251-7 · doi:10.1016/s0960-894x(01)00251-7
- 10.1517/17425250902988487 · doi:10.1517/17425250902988487
- Ryder, N. S. 2009. Discontinued drugs in 2008: anti-infectives. Expert Opin. Invest. Drugs 19 : 1-21.
- 10.1093/oxfordjournals.jbchem.a130606 · doi:10.1093/oxfordjournals.jbchem.a130606
- 10.1159/000472864 · doi:10.1159/000472864
- 10.7164/antibiotics.50.22 · doi:10.7164/antibiotics.50.22
- 10.1517/14728220903005590 · doi:10.1517/14728220903005590
- Silver, L. L. 2005. A retrospective on the failures and successes of antibacterial drug discovery. IDrugs 8 : 651-655.
- 10.1016/j.bcp.2005.10.029 · doi:10.1016/j.bcp.2005.10.029
- Skipper, H. E., J. R. Thomson, and M. Bell. 1954. Attempts at dual blocking of biochemical events in cancer chemotherapy. Cancer Res. 14 : 503-507.
- 10.1111/j.1464-410X.1963.tb02604.x · doi:10.1111/j.1464-410x.1963.tb02604.x
- 10.1128/jb.132.1.73-79.1977 · doi:10.1128/jb.132.1.73-79.1977
- 10.1111/j.1747-0285.2005.00317.x · doi:10.1111/j.1747-0285.2005.00317.x
- 10.1128/am.6.6.392-398.1958 · doi:10.1128/am.6.6.392-398.1958
- 10.1016/j.bmcl.2009.07.141 · doi:10.1016/j.bmcl.2009.07.141
- 10.1021/jm030394f · doi:10.1021/jm030394f
- 10.1016/j.bmcl.2005.06.103 · doi:10.1016/j.bmcl.2005.06.103
- 10.1021/jo951780a · doi:10.1021/jo951780a
- Tomasic, T., N. Zidar, A. Kovac, S. Turk, M. Simcic, D. Blanot, M. Müller-Premru, M. Filipic, S. Golic Grdadolnik, A. Zega, M. Anderluh, S. Gobec, D. Kikelj, and L. P. Masic. 2009. 5-Benzylidenethiazolidin-4-ones as multitarget inhibitors of bacterial Mur ligases. ChemMedChem 5 : 286-295.
- 10.1054/drup.1999.0111 · doi:10.1054/drup.1999.0111
- Tung, R. D. 2002. Design and synthesis of amprenavir, a novel HIV protease inhibitor. Infect. Dis. Ther. 25 : 101-118.
- 10.1016/j.bmc.2009.01.052 · doi:10.1016/j.bmc.2009.01.052
- 10.1111/j.1365-2885.1994.tb00251.x · doi:10.1111/j.1365-2885.1994.tb00251.x
- 10.7164/antibiotics.56.1045 · doi:10.7164/antibiotics.56.1045
- 10.1016/j.bmcl.2007.03.004 · doi:10.1016/j.bmcl.2007.03.004
- Woodruff, H. B., J. M. Mata, S. Hernàndez, S. Mochales, A. Rodríguez, E. O. Stapley, H. Wallick, A. K. Miller, and D. Hendlin. 1977. Fosfomycin: laboratory studies. Chemotherapy 23 : 1-22.
- 10.1111/j.1749-6632.1974.tb43292.x · doi:10.1111/j.1749-6632.1974.tb43292.x
Cited by
Antibiotic resistance threats in the United States, 2019
(U.S.), C. F. D. C. A. P. (2019) · doi:10.15620/cdc:82532 · Cited by 5,782
The re-emergence of natural products for drug discovery in the genomics era
Harvey, A. L., Edrada-Ebel, R., & Quinn, R. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4510 · Cited by 2,572
Antibacterial drug discovery in the resistance era
Brown, E. D., & Wright, G. D. (2016) · Nature · doi:10.1038/nature17042 · Cited by 2,247
Antibiotics and Bacterial Resistance in the 21st Century
Fair, R. J., & Tor, Y. (2014) · Perspectives in Medicinal Chemistry · doi:10.4137/pmc.s14459 · Cited by 1,955
The Challenge of Efflux-Mediated Antibiotic Resistance in Gram-Negative Bacteria
Li, X.-Z., Plésiat, P., & Nikaido, H. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00117-14 · Cited by 1,614
Metadata
- Authors
- Silver, L. L.
- Venue
- Clinical Microbiology Reviews
- Publisher
- American Society for Microbiology
- Published
- 2011-01
- Volume
- 24
- Issue
- 1
- Pages
- 71-109
- ISSN
- 0893-8512 (ISSN-L)
- 1098-6618
- OpenAlex
- W2139516496
- Cited by
- 1,376
- References
- 287
- FWCI
- 27.74
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.